Ultra Market Research | Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
Report ID : 855
Category : Pharmaceuticals,Europe
No Of Pages : 187
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
Introduction
The Europe ATTR-CM market encompasses the diagnosis and treatment of transthyretin amyloid cardiomyopathy, a progressive disease caused by amyloid protein deposits in the heart. ATTR-CM can manifest as hereditary or wild-type forms, both significantly impacting cardiac functionality. With increasing disease awareness and advanced healthcare infrastructure, Europe has seen substantial growth in ATTR-CM diagnostics and treatment options. The region benefits from ongoing clinical trials, innovative therapeutics, and improved diagnostic imaging technologies. Recent trends highlight the growing adoption of biomarker testing and gene-silencing therapies, propelling market expansion. The Europe ATTR-CM market is poised for growth due to rising prevalence rates, particularly in aging populations, and favorable government healthcare initiatives aimed at addressing rare diseases.
Segmentation
By Treatment Type
Pharmacological Therapies
Tafamidis
Diflunisal
Non-steroidal anti-inflammatory Drugs (NSAIDs)
Others
Gene Silencing Therapies
Patisiran
Inotersen
Supportive Therapies
Beta-Blockers
Diuretics
Anti-arrhythmic Drugs
By Diagnostics
Imaging Techniques
Echocardiography
Cardiac MRI
Nuclear Imaging
Others
Biomarker Testing
NT-proBNP Testing
Troponin Testing
Others
Genetic Testing
Mutation Analysis
Family History Testing
By End-User
Hospitals and Clinics
Cardiology Departments
Specialty Clinics
Diagnostic Laboratories
Independent Laboratories
Hospital-Affiliated Labs
Research and Academic Institutes
By Distribution Channel
Hospital Pharmacies
Inpatient Dispensing
Specialty Drug Distribution
Retail Pharmacies
Chain Pharmacies
Standalone Pharmacies
Online Pharmacies
List of Market Players
Pfizer Inc. (United States)
Alnylam Pharmaceuticals (United States)
Eidos Therapeutics (United States)
Ionis Pharmaceuticals (United States)
BridgeBio Pharma (United States)
AstraZeneca (United Kingdom)
GlaxoSmithKline (United Kingdom)
Johnson & Johnson (United States)
Novartis AG (Switzerland)
Sanofi (France)
Prothena Corporation (United States)
Regeneron Pharmaceuticals (United States)
Merck & Co. (United States)
Amgen Inc. (United States)
Bristol-Myers Squibb (United States)
Drivers
The Europe ATTR-CM market is driven by advancements in medical diagnostics and therapeutics targeting rare diseases. The rising prevalence of ATTR-CM, particularly among aging populations, has created significant demand for effective diagnostic and treatment solutions. Improved healthcare infrastructure and reimbursement policies in Europe have enabled widespread adoption of advanced imaging technologies and genetic testing. Clinical trials and innovative therapeutic approaches, such as gene-silencing therapies and transthyretin stabilizers, have enhanced the treatment landscape. Additionally, increasing disease awareness campaigns and collaborations between pharmaceutical companies and healthcare providers further accelerate market growth.
Restraints
The high cost of ATTR-CM treatments and diagnostic tools limits market accessibility, especially in low-income areas of Europe. Limited awareness about the condition among general practitioners leads to delayed diagnoses, affecting treatment outcomes. Regulatory hurdles and stringent approval processes for new therapeutics create barriers for market entry, particularly for emerging players. The rarity of the disease poses challenges in conducting large-scale clinical trials, hindering research and development. Additionally, disparities in healthcare access across European countries restrict market penetration, affecting overall growth.
Opportunity
The Europe ATTR-CM market offers significant growth opportunities through advancements in diagnostic imaging and targeted therapies. Increased investment in research and development is driving innovation, particularly in RNA-based therapeutics and personalized medicine approaches. Collaborations between pharmaceutical companies and academic institutions can enhance drug discovery and accelerate approvals. Expanding telemedicine services and mobile diagnostic units can improve access to care in remote areas. Government initiatives focused on rare diseases, along with patient advocacy groups, can further promote early diagnosis and effective treatment, unlocking the market’s full potential.
Trend
The ATTR-CM market in Europe is marked by trends such as the integration of artificial intelligence (AI) in diagnostic imaging to improve accuracy and efficiency. Precision medicine, targeting genetic mutations specific to ATTR-CM, is gaining momentum. Increasing use of wearable health monitoring devices aids in early detection and ongoing patient management. Expansion of clinical trial networks across Europe supports accelerated drug development. Partnerships between biotech firms and healthcare providers focus on creating innovative care models, aligning with patient-centric healthcare approaches.
A rare condition caused by amyloid deposits in the heart, affecting its function.
Rising prevalence, advanced diagnostics, and innovative therapeutic options.
Cardiac imaging, biomarker testing, and genetic screening are prevalent.
Pfizer, Alnylam Pharmaceuticals, and Novartis are key contributors.
AI in diagnostics, wearable health technologies, and precision medicine are leading trends.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis 2. Market Dashboard 3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Treatment Type 3.2.2 By Diagnostics 3.2.3 By End-User 3.2.4 By Distribution Channel 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges 4. Europe ATTR-CM Market by Treatment Type 4.1 Introduction 4.2 Market Size and Growth Rate by Treatment Type (2024-2030) 4.2.1 Pharmacological Therapies 4.2.1.1 Tafamidis 4.2.1.2 Diflunisal 4.2.1.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 4.2.1.4 Others 4.2.2 Gene Silencing Therapies 4.2.2.1 Patisiran 4.2.2.2 Inotersen 4.2.3 Supportive Therapies 4.2.3.1 Beta-Blockers 4.2.3.2 Diuretics 4.2.3.3 Anti-arrhythmic Drugs 5. Europe ATTR-CM Market by Diagnostics 5.1 Introduction 5.2 Market Size and Growth Rate by Diagnostics (2024-2030) 5.2.1 Imaging Techniques 5.2.1.1 Echocardiography 5.2.1.2 Cardiac MRI 5.2.1.3 Nuclear Imaging 5.2.1.4 Others 5.2.2 Biomarker Testing 5.2.2.1 NT-proBNP Testing 5.2.2.2 Troponin Testing 5.2.2.3 Others 5.2.3 Genetic Testing 5.2.3.1 Mutation Analysis 5.2.3.2 Family History Testing 6. Europe ATTR-CM Market by End-User 6.1 Introduction 6.2 Market Size and Growth Rate by End-User (2024-2030) 6.2.1 Hospitals and Clinics 6.2.1.1 Cardiology Departments 6.2.1.2 Specialty Clinics 6.2.2 Diagnostic Laboratories 6.2.2.1 Independent Laboratories 6.2.2.2 Hospital-Affiliated Labs 6.2.3 Research and Academic Institutes 7. Europe ATTR-CM Market by Distribution Channel 7.1 Introduction 7.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 7.2.1 Hospital Pharmacies 7.2.1.1 Inpatient Dispensing 7.2.1.2 Specialty Drug Distribution 7.2.2 Retail Pharmacies 7.2.2.1 Chain Pharmacies 7.2.2.2 Standalone Pharmacies 7.2.3 Online Pharmacies 8. Competitive Landscape 8.1 Company Profiles 8.1.1 Pfizer Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Alnylam Pharmaceuticals (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.3 Eidos Therapeutics (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.4 Ionis Pharmaceuticals (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.5 BridgeBio Pharma (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.6 AstraZeneca (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.7 GlaxoSmithKline (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.8 Johnson & Johnson (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.9 Novartis AG (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.10 Sanofi (France) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.11 Prothena Corporation (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.12 Regeneron Pharmaceuticals (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.13 Merck & Co. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.14 Amgen Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.15 Bristol-Myers Squibb (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9. Conclusion and Recommendations 10. List of Tables and Figures 10.1 List of Tables Table Europe ATTR-CM Market Size by Treatment Type (2024-2030) Table Pharmacological Therapies Market Size by Sub-type (2024-2030) Table Gene Silencing Therapies Market Size by Sub-type (2024-2030) Table Supportive Therapies Market Size by Sub-type (2024-2030) Table Diagnostics Market Size by Sub-type (2024-2030) Table Imaging Techniques Market Size by Sub-type (2024-2030) Table Biomarker Testing Market Size by Sub-type (2024-2030) Table Genetic Testing Market Size by Sub-type (2024-2030) Table Europe ATTR-CM Market Size by End-User (2024-2030) Table Hospitals and Clinics Market Size by Sub-type (2024-2030) Table Diagnostic Laboratories Market Size by Sub-type (2024-2030) Table Europe ATTR-CM Market Size by Distribution Channel (2024-2030) Table Hospital Pharmacies Market Size by Sub-type (2024-2030) Table Retail Pharmacies Market Size by Sub-type (2024-2030) 10.2 List of Figures Figure Europe ATTR-CM Market Size and Growth Rate by Treatment Type (2024-2030) Figure Pharmacological Therapies Market Growth Rate by Sub-type (2024-2030) Figure Gene Silencing Therapies Market Growth Rate by Sub-type (2024-2030) Figure Supportive Therapies Market Growth Rate by Sub-type (2024-2030) Figure Diagnostics Market Growth Rate by Sub-type (2024-2030) Figure Imaging Techniques Market Growth Rate by Sub-type (2024-2030) Figure Biomarker Testing Market Growth Rate by Sub-type (2024-2030) Figure Genetic Testing Market Growth Rate by Sub-type (2024-2030) Figure Europe ATTR-CM Market Size and Growth Rate by End-User (2024-2030) Figure Europe ATTR-CM Market Size and Growth Rate by Distribution Channel (2024-2030) Tables Financial Overview of Key Companies Table Pfizer Inc. ATTR-CM Financial Overview Table Alnylam Pharmaceuticals ATTR-CM Financial Overview Table Eidos Therapeutics ATTR-CM Financial Overview Table Ionis Pharmaceuticals ATTR-CM Financial Overview Table BridgeBio Pharma ATTR-CM Financial Overview Table AstraZeneca ATTR-CM Financial Overview Table GlaxoSmithKline ATTR-CM Financial Overview Table Johnson & Johnson ATTR-CM Financial Overview Table Novartis AG ATTR-CM Financial Overview Table Sanofi ATTR-CM Financial Overview Table Prothena Corporation ATTR-CM Financial Overview Table Regeneron Pharmaceuticals ATTR-CM Financial Overview Table Merck & Co. ATTR-CM Financial Overview Table Amgen Inc. ATTR-CM Financial Overview Table Bristol-Myers Squibb ATTR-CM Financial Overview
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Europe market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Europely. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market for the past year and forecasts for the next six years. Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market categories. Market size and forecasts for each major application is provided in the context of Europe market. The numbers provided in this report are derived on the basis of demand for Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market from different application industries in different regions.
